WASHINGTON — President Trump moved on Saturday to “reverse the crisis of serious mental illness in America” by boosting access to psychedelic drugs in clinical settings. In an executive order, he directed the federal government to rush access to treatments and reevaluate their status as controlled substances.
The order directs the Food and Drug Administration to expedite some psychedelics as breakthrough drugs, as well as allowing them to be used through right-to-try legislation, which permits terminally ill patients to try experimental drugs outside of usual regulatory pathways. This shift could significantly alter the landscape of mental health treatment, providing new avenues for patients who have not responded to traditional therapies.
The implications of this executive action extend beyond immediate patient care, potentially reshaping the regulatory framework for drug approval and encouraging further investment in psychedelic research. As the pharmaceutical industry adapts to these changes, stakeholders in regulatory, QA/QC, and CMC sectors will need to align their strategies with the evolving landscape of mental health therapeutics.
Use the database as your supply chain compass →
